Grufity logo
Grufity logo
CGEM

CGEM - Cullinan Management, Inc. Stock Price, Fair Value and News

$17.64-0.11 (-0.62%)
Delayed as of 24 Jun 2026, 04:00 pm ET

Price Targets

CGEM Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CGEM Price Action

Last 7 days

22.2%

Last 30 days

27.5%

Last 90 days

29.0%

Trailing 12 Months

125%

CGEM RSI Chart

CGEM Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CGEM Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

-4.9

Price/Sales (Trailing)

53.33

EV/EBITDA

-4.6

Price/Free Cashflow

-6.07

CGEM Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

CGEM Fundamentals

CGEM Revenue

Revenue (TTM)

18.9M

CGEM Earnings

Earnings (TTM)

-221.0M

Earnings Growth (Yr)

-2.39%

Earnings Growth (Qtr)

2.07%

CGEM Profitability

EBT Margin

-1160.74%

Return on Equity

-60.36%

Return on Assets

-54.85%

Free Cashflow Yield

-16.48%

CGEM Investor Care

Shares Dilution (1Y)

4.70%

Revenue & Growth

How Cullinan Management, Inc. generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2021---18.9M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Cullinan Management, Inc.

CGEM
Cullinan Oncology, Inc. a clinical-stage biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally bioavailable small-molecule that is in a Phase IIb dose escalation for treating patients with non-small cell lung cancer. Its products also include CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors; and CLN-418, a human bispecific antibody that is in Phase 1 clinical trial for the treatment of solid tumors. In addition, the company's preclinical product includes CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEcullinanoncology.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES62

Cullinan Management, Inc. Frequently Asked Questions

CGEM is the stock ticker symbol of Cullinan Management, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jun 24 2026, market cap of Cullinan Management, Inc. is 1.08 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Wed Jun 24 2026, CGEM's PE ratio (Price to Earnings) is -4.9 and Price to Sales (PS) ratio is 53.33. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CGEM PE ratio will change depending on the future growth rate expectations of investors.